ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
2,4,Staphylococcal sepsis,Staphylococcal infections,Bacterial infectious disorders,Infec,N
3,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
5,1,Coagulation factor VIII level abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
6,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
